Notable 52-Week Highs and Lows 10/3: (NVFY) (BLDP) (PTC) High; (VNR) (CXRX) (HRTX) Low

October 3, 2016 2:34 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

52-Week High:
  • Nova LifeStyle, Inc. (Nasdaq: NVFY) $5.14. Nova LifeStyle continuing higher from last Friday after anouncing that it signed a Share Transfer Agreement with Kuka Design Limited, a company incorporated in BVI (“Kuka BVI”) to sell NOVA BVI and its subsidiaries, which consists of the Company’s manufacturing operations in mainland China.

  • Ballard Power Systems (Nasdaq: BLDP $2.52. Ballard Power adding to strong gains from last week after inking an agreement with Audi and getting a fuel-cell bus order in China.

  • PTC (Nasdaq: PTC) $46.80. PTC announced that preliminary bookings for the fourth fiscal quarter ended September 30, 2016 are expected to be between $139 million and $142 million, above the high end of the company’s previous guidance of $111 million to $121 million. There are two mega deals (>$5 million in bookings) in the quarter, including a competitive PLM displacement within one of the top Tier 1 global automotive suppliers, and a worldwide cloud implementation of PTC’s service parts management solution – both a testament to PTC’s leading technology position in these markets.
52-Week Low:
  • Vanguard Natural Resources, LLC (Nasdaq: VNR) $0.81. Vanguard Natural Resources announced that it has elected not to make the approximately $15 million semi-annual interest payment due on October 3, 2016 on approximately $381.8 million in aggregate principal amount of 7.785% of Senior Notes due 2020.Vanguard made the decision to take advantage of the applicable grace period under the indenture governing the Notes following discussions with Vanguard’s lenders under its first lien credit facility.

  • Concordia International Corp. (Nasdaq: CXRX) $4.43. Concordia International announced that it has exercised an option to defer half of the anticipated £144 million earn-out obligation due to Cinven1 and the other sellers of Concordia's International segment, to February 1, 2017.

  • Heron Therapeutics (Nasdaq: HRTX) $15.13. Heron Therapeutics disclosed late last Friday that it accepted the resignations of Neil J. Clendeninn, M.D., Ph.D., the Company’s Senior Vice President, Chief Medical Officer, Paul G. Marshall, the Company’s Senior Vice President, Technical Operations, and Brian G. Drazba, the Company’s Vice President, Finance and Chief Financial Officer. The resignations of Dr. Clendeninn and Mr. Marshall are effective as of September 30, 2016.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Vanguard

Add Your Comment